Jorge S Reis-Filho Selected Research

Adenomyoepithelioma

1/2021	Problematic breast tumors reassessed in light of novel molecular data.
1/2018	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jorge S Reis-Filho Research Topics

Disease

200	Neoplasms (Cancer) 04/2022 - 01/2002
135	Breast Neoplasms (Breast Cancer) 01/2022 - 06/2002
28	Carcinoma (Carcinomatosis) 11/2021 - 12/2002
17	Triple Negative Breast Neoplasms 04/2022 - 09/2008
11	Neoplasm Metastasis (Metastasis) 11/2021 - 09/2008
9	Lobular Carcinoma 01/2021 - 01/2005
8	Carcinogenesis 01/2022 - 01/2007
8	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 09/2011
8	Melanoma (Melanoma, Malignant) 10/2020 - 01/2003
8	Ductal Carcinoma 12/2014 - 04/2009
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 12/2002
5	Adenocarcinoma 01/2022 - 01/2003
4	Disease Progression 07/2021 - 11/2012
4	Lung Neoplasms (Lung Cancer) 01/2021 - 01/2014
4	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2021 - 04/2008
4	Papillary Carcinoma 01/2020 - 02/2012
4	Endometrial Neoplasms (Endometrial Cancer) 01/2016 - 10/2010
3	Residual Neoplasm 01/2022 - 08/2015
3	Chromosomal Instability (Chromosome Stability) 01/2022 - 11/2010
3	Mucinous Adenocarcinoma (Mucinous Carcinoma) 01/2021 - 01/2019
3	Genomic Instability 01/2020 - 02/2008
3	Acinar Cell Carcinoma 12/2019 - 10/2015
3	Brain Neoplasms (Brain Tumor) 04/2018 - 01/2007
3	Metaplasia 01/2017 - 12/2002
3	Fibrocystic Breast Disease (Chronic Cystic Mastitis) 01/2017 - 01/2013
3	Sarcoma (Soft Tissue Sarcoma) 01/2016 - 01/2005
3	Breast Carcinoma In Situ 04/2015 - 04/2002
3	Glioblastoma (Glioblastoma Multiforme) 01/2014 - 01/2003
3	Wilms Tumor (Wilm's Tumor) 04/2009 - 12/2006
2	Pathologic Complete Response 04/2022 - 12/2010
2	Fibroadenoma 02/2022 - 11/2015
2	Inflammation (Inflammations) 01/2021 - 01/2016
2	Adenoid Cystic Carcinoma (Cylindroma) 01/2021 - 03/2010
2	Adenomyoepithelioma 01/2021 - 01/2018
2	Hypoxia (Hypoxemia) 01/2021 - 12/2019
2	DNA Repair-Deficiency Disorders (Chromosome Instability Syndromes) 01/2020 - 01/2017

Drug/Important Bio-Agent (IBA)

41	Estrogen ReceptorsIBA 01/2022 - 07/2005
36	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 02/2006
36	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2002
30	Phenobarbital (Luminal)FDA Link 01/2020 - 05/2004
24	Biological ProductsIBA 01/2022 - 01/2003
20	Progesterone Receptors (Progesterone Receptor)IBA 01/2022 - 03/2004
20	Biomarkers (Surrogate Marker)IBA 11/2021 - 07/2008
13	RNA (Ribonucleic Acid)IBA 01/2022 - 10/2011
13	Cadherins (E-Cadherin)IBA 01/2021 - 04/2002
12	Hormones (Hormone)IBA 01/2022 - 07/2006
12	Phosphotransferases (Kinase)IBA 01/2021 - 02/2007
10	AnthracyclinesIBA 01/2011 - 01/2007
9	AntibodiesIBA 09/2021 - 01/2005
9	ParaffinIBA 10/2019 - 12/2002
8	Monoclonal AntibodiesIBA 01/2021 - 01/2003
8	Formaldehyde (Formol)FDA Link 10/2019 - 01/2005
8	ErbB Receptors (EGF Receptor)IBA 10/2012 - 01/2005
7	CateninsIBA 01/2021 - 10/2010
7	Messenger RNA (mRNA)IBA 01/2020 - 12/2006
6	Transcription Factors (Transcription Factor)IBA 01/2022 - 02/2011
6	Pharmaceutical PreparationsIBA 01/2021 - 03/2011
6	Poly(ADP-ribose) Polymerase InhibitorsIBA 11/2017 - 02/2008
6	Cyclin D1IBA 11/2010 - 04/2006
5	Keratins (Keratin)IBA 01/2020 - 08/2003
5	Trastuzumab (Herceptin)FDA Link 01/2020 - 05/2008
5	Indicators and Reagents (Reagents)IBA 04/2015 - 09/2004
5	AntigensIBA 04/2014 - 06/2007
4	human ERBB2 proteinIBA 01/2022 - 02/2011
4	Immune Checkpoint InhibitorsIBA 12/2021 - 01/2020
4	Circulating Tumor DNAIBA 07/2021 - 10/2013
4	Cell-Free Nucleic AcidsIBA 01/2021 - 07/2013
4	Lapatinib (GW572016)FDA Link 01/2020 - 09/2017
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020 - 01/2003
4	Keratin-14 (Keratin 14)IBA 10/2013 - 08/2003
4	LigandsIBA 08/2011 - 01/2005
3	Small Interfering RNA (siRNA)IBA 01/2022 - 01/2016
3	Mitogen-Activated Protein KinasesIBA 01/2022 - 03/2010
3	NucleotidesIBA 01/2022 - 02/2012
3	B7-H1 AntigenIBA 01/2022 - 01/2021
3	ChromatinIBA 10/2021 - 01/2002
3	Tumor Biomarkers (Tumor Markers)IBA 01/2021 - 08/2007
3	Cyclin-Dependent Kinase 4IBA 01/2021 - 04/2006
3	MucinsIBA 01/2021 - 01/2019
3	Aromatase InhibitorsIBA 10/2020 - 03/2015
3	VimentinIBA 01/2020 - 11/2005
3	PlatinumIBA 01/2020 - 11/2010
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019 - 12/2009
3	ClaudinsIBA 01/2017 - 02/2012
3	Phosphatidylinositols (Phosphatidylinositol)IBA 05/2014 - 03/2010
3	Androgen Receptors (Androgen Receptor)IBA 12/2013 - 02/2012
3	OligonucleotidesIBA 02/2012 - 11/2009
3	Caveolin 1IBA 01/2012 - 01/2007
2	Mediator ComplexIBA 02/2022 - 11/2015
2	Eosine Yellowish-(YS) (Eosin)IBA 01/2022 - 01/2020
2	Hematoxylin (Haematoxylon)IBA 01/2022 - 01/2020
2	Adenosine Triphosphatases (ATPase)IBA 01/2022 - 10/2021
2	atezolizumabIBA 01/2022 - 01/2021
2	Protein Isoforms (Isoforms)IBA 01/2021 - 01/2002

Therapy/Procedure

68	Therapeutics 01/2022 - 01/2005
25	Drug Therapy (Chemotherapy) 01/2020 - 12/2006
13	Neoadjuvant Therapy 04/2022 - 06/2009
6	Immunotherapy 01/2022 - 01/2014
5	Radiotherapy 01/2021 - 01/2007
3	Precision Medicine 10/2017 - 07/2013